Soochow University

THURSDAY, Feb. 6, 2025 -- For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology shows promise for improving urinary symptoms while better preserving ejaculatory function, according to a study published online Jan. 10 in the World Journal of Urology . Zhixiang Gao, from Zhangjiagang Hospital Affiliated to Soochow University in Suzhou, China, and colleagues conducted a multicenter, prospective, single-blind, randomized controlled trial involving sexually active men with BPH. Participants were randomly allocated to standard HoLEP, single-n technology, and innovative double-n technology (groups A, B, and C, respectively). A total of 139 participants completed the study. The researchers found that all groups had significant improvements in maximum urinary flow rate and the International Prostate Symptom Score. Across all groups, there were initial declines in International Index of Erectile Function scores, stabilizing to baseline by three months, with no additional improvement observed. Modest antegrade ejaculation rates were seen in group A, starting at 15.4 percent at three months and reaching 23.1 percent at 12 months. In groups B and C, significant improvement was seen, with antegrade ejaculation rates increasing from 31.8 to 45.5 percent and from 57.8 to 77.8 percent, respectively. Group A had 100 percent semen reduction at three months, decreasing to 77.8 percent at 12 months. A similar trend was seen in Group B (100 and 68.2 percent, respectively), while a more pronounced decline was seen in Group C, from 84.6 to 37.1 percent, respectively. "The Double-n HoLEP represents a significant step forward in the surgical management of BPH, especially for patients concerned about preserving sexual function postoperatively," the authors write.

TUESDAY, July 9, 2024 -- For childhood cancer survivors, there are racial and ethnic disparities in epigenetic age acceleration (EAA), which are partially mediated by social determinants of health (SDOH), according to a study published online July 2 in JAMA Network Open . Cheng Chen, from The Fourth Affiliated Hospital of Soochow University in Suzhou, China, and colleagues compared non-Hispanic Black to non-Hispanic White survivors of childhood cancer by examining the associations of EAA with cancer treatment exposures and mediating roles of SDOH in a cross-sectional study. Data were included for 1,706 survivors, including 230 and 1,476 non-Hispanic Black and non-Hispanic White survivors, respectively. The researchers found that EAA was significantly greater among non-Hispanic Black versus non-Hispanic White survivors (adjusted least-square means [ALSM], 1.41 and 0.47, respectively). Among non-Hispanic Black survivors, EAA was significantly increased among those exposed versus unexposed to chest radiotherapy (ALSM, 2.82 versus 0.46); among those exposed versus unexposed to alkylating agents (ALSM, 2.33 versus 0.95); and among those exposed versus unexposed to epipodophyllotoxins (ALSM, 2.83 versus 0.44). The association with epipodophyllotoxins differed by race and ethnicity (β, 2.39 and 0.68 years for non-Hispanic Black and non-Hispanic White survivors, respectively). Educational attainment and socioeconomic area deprivation index mediated racial and ethnic disparities in EAA (mediation, 22.71 and 22.16 percent, respectively). "This finding suggests that changes in the social support system at both the personal and community levels may mitigate socioeconomic disadvantages that may contribute to the development of an aging phenotype," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

6月27日下午，苏州大学研究生工作站（实践基地）授牌暨药学院产教融合创新基地签约与产业教授（兼职导师）聘任仪式在药学院云轩楼1323会议室举行。药学院领导、苏州生物医药产业园领导、生物医药企业负责人及专家等30余人出席活动。 药学院党委书记王欣宣读《关于公布2023年苏州大学硕士专业学位研究生实践基地和第十四批研究生工作站名单的通知》、《药学院关于聘任初虹等同志为药学院产业教授的通知》、《药学院关于聘任第三批实践基地兼职导师的通知》等文件。药学院副院长汪维鹏为药学院产业教授及兼职导师代表颁发证书，我司创始人杨志伟博士被聘为苏大药学院产业教授。被聘为苏大药学院产业教授的还有吉玛基因的创始人张佩琢博士、苏州锐明的创始人张飞博士、比邻星创投的创始人杨俊杰博士等。 会议还围绕人才培养、项目合作、平台共建共享等进行座谈交流，各位企业负责人、专家畅所欲言，介绍了企业发展情况及产学研合作方面的需求，对加强产学研合作具体措施和行动方案提出了宝贵意见和建议。 关于杨志伟博士： 杨志伟，在北京大学获得学士和硕士学位，美国哥伦比亚大学获有机化学博士学位，美国加州理工学院和哈佛大学从事化学生物学博士后研究。在美国Schering-Plough制药公司从事新药研发，美国 Life Technologies公司负责基因转染试剂和生物技术开发，是Lipofectamine系列转染试剂的负责人。2014年回国后，曾任北京化工大学教授，北京大学分子工程苏南研究院集萃研究员。于2022年创立了苏州时安生物技术有限公司，担任董事长和CTO，从事核酸创新药的开发。杨志伟博士曾在JACS，PNAS，BMCL等期刊上发表多篇论文，申请了40多项国际和国内专利。